Galmed Pharmaceuticals is a clinical-stage company focused on developing therapeutics for liver diseases, including its oral therapy Aramchol in Phase III study for patients with non-alcoholic steato-hepatitis. They are evaluating Aramchol through the ARRIVE study for HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed has research agreements with Gannex Pharma and MyBiotics Pharma, as well as a license agreement with Samil Pharma for commercialization of Aramchol in the Republic of Korea.